These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9576415)

  • 21. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.
    Shaffer D; Singer S; Korvick J; Honig P
    Clin Infect Dis; 2002 Jul; 35(2):197-200. PubMed ID: 12087527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiological and pathological responses of TU waves to class Ia antiarrhythmic drugs.
    Maruyama T; Ohe T; Kurita T; Aihara N; Shimizu W
    Eur Heart J; 1995 May; 16(5):667-73. PubMed ID: 7588899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
    Lin JC; Quasny HA
    Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Commentary-QT prolongation due to roxithromycin.
    Malcolm A
    Postgrad Med J; 2000 Oct; 76(900):653-4. PubMed ID: 11009582
    [No Abstract]   [Full Text] [Related]  

  • 25. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Case of QT Prolongation and Torsades de Pointes Caused by Ibogaine Toxicity.
    Hildyard C; Macklin P; Prendergast B; Bashir Y
    J Emerg Med; 2016 Feb; 50(2):e83-7. PubMed ID: 26329675
    [No Abstract]   [Full Text] [Related]  

  • 27. QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin.
    Kyrmizakis DE; Chimona TS; Kanoupakis EM; Papadakis CE; Velegrakis GA; Helidonis ES
    Am J Otolaryngol; 2002; 23(5):303-7. PubMed ID: 12239699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prolongation of the QT interval and torsade de pointes caused by ketanserin].
    Arfiero S; Ometto R; Vincenzi M
    G Ital Cardiol; 1990 Sep; 20(9):869-72. PubMed ID: 2079190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug induced QT prolongation and torsades de pointes.
    Yap YG; Camm AJ
    Heart; 2003 Nov; 89(11):1363-72. PubMed ID: 14594906
    [No Abstract]   [Full Text] [Related]  

  • 30. Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review.
    Khan F; Ismail M; Khan Q; Ali Z
    Expert Opin Drug Saf; 2018 Oct; 17(10):1029-1039. PubMed ID: 30193085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QT prolongation and Torsades de Pointes after administration of FK506.
    Johnson MC; So S; Marsh JW; Murphy AM
    Transplantation; 1992 Apr; 53(4):929-30. PubMed ID: 1373538
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug-induced QT prolongation and sudden death.
    Del Rosario ME; Weachter R; Flaker GC
    Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes.
    Isbister GK; Balit CR; Macleod D; Duffull SB
    J Clin Psychopharmacol; 2010 Aug; 30(4):391-5. PubMed ID: 20531221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QT interval prolongation as a biomarker for torsades de pointes and sudden death in drug development.
    Sides GD
    Dis Markers; 2002; 18(2):57-62. PubMed ID: 12364811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrolides use and the risk of sudden cardiac death.
    Li X; Wang M; Liu G; Zhou L; Wang Z; Li C
    Expert Rev Anti Infect Ther; 2016 Jun; 14(6):535-7. PubMed ID: 27086751
    [No Abstract]   [Full Text] [Related]  

  • 36. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged QT: A rare cause of cardiac arrest.
    Carlquist J
    JAAPA; 2015 Aug; 28(8):. PubMed ID: 26208008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs and the QT interval - caveat doctor.
    Liu BA; Juurlink DN
    N Engl J Med; 2004 Sep; 351(11):1053-6. PubMed ID: 15356302
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.
    Iannini PB; Doddamani S; Byazrova E; Curciumaru I; Kramer H
    BMJ; 2001 Jan; 322(7277):46-7. PubMed ID: 11141163
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.
    Yap YG; Camm J
    BMJ; 2000 Apr; 320(7243):1158-9. PubMed ID: 10784527
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.